Your session is about to expire
← Back to Search
PDE4 Inhibitor
PDE4 Inhibitor for Skin Conditions
Phase 2
Recruiting
Led By Benjamin Ungar, MD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child
Diagnosis of SD and baseline IGA ≥ 3 with facial involvement OR Diagnosis of PPR, baseline IGA ≥ 3, and baseline inflammatory lesion count ≥ 12
Must not have
Use of systemic biologic immunosuppressive medications within 12 weeks of baseline
Subject has previously received treatment with oral or topical PDE4 inhibitors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 8 weeks, 12 weeks
Summary
This trial will test a new ointment to treat skin conditions Seborrheic Dermatitis and Papulopustular Rosacea in adults. Subjects will apply ointment once daily for 8 weeks and be monitored for improvement.
Who is the study for?
Adults over 18 with moderate-to-severe Seborrheic Dermatitis (SD) or Papulopustular Rosacea (PPR), who have specific severity scores and agree to avoid other treatments during the study. Participants must use effective contraception, be in good health, and not have used certain medications recently.
What is being tested?
The trial is testing PF-07038124 ointment against a placebo for SD and PPR. It's double-blind, meaning neither participants nor researchers know who gets the real treatment. Subjects apply it daily for 8 weeks with follow-ups at weeks 4, 8, and 12.
What are the potential side effects?
While specific side effects of PF-07038124 are not listed here, common side effects of topical treatments may include skin irritation, redness, itching or burning sensation at the application site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am willing to use birth control to prevent pregnancy or fathering a child.
Select...
My skin condition is severe with significant facial involvement.
Select...
I am 18 years or older and have signed the consent form.
Select...
I agree to stop all other treatments for my skin condition during the study, except for the study drug.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I haven't taken any immune-weakening drugs in the last 12 weeks.
Select...
I have taken PDE4 inhibitors before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 8 weeks, 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 8 weeks, 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Subjects reaching Investigator's Global Assessment (IGA) success - Seborrheic dermatitis (SD)
Percent change in lesion count Papulopustular Rosacea (PPR)
Secondary study objectives
Change in Clinical Erythema - PPR
Change in IGA Score - SD and PPR
Change in Lesion count - PPR
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-07038124Experimental Treatment1 Intervention
PF-07038124 0.02% ointment once daily for 8 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo Ointment
Find a Location
Who is running the clinical trial?
PfizerIndustry Sponsor
4,675 Previous Clinical Trials
28,717,116 Total Patients Enrolled
Icahn School of Medicine at Mount SinaiLead Sponsor
914 Previous Clinical Trials
572,835 Total Patients Enrolled
Benjamin Ungar, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
1 Previous Clinical Trials
45 Total Patients Enrolled